期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 81, 期 1, 页码 35-41出版社
WILEY
DOI: 10.1038/sj.clpt.6100016
关键词
-
资金
- NHLBI NIH HHS [R01 HL075495-01A2, R01 HL075495] Funding Source: Medline
The cardiac sodium channel (SCN5A) is a target for the treatment of arrhythmias. We hypothesized that vulnerability to atrial fibrillation (AF) could be caused by genetic variation in SCN5A. We recruited 157 patients with early-onset AF who lacked traditional risk factors, and 314 matched controls. SCN5A was subject to targeted genotyping of a common loss-of-function H558R polymorphism and comprehensive mutation scanning. Genotype frequencies in the AF cohort vs controls were as follows: HH, 50 vs 63%; HR, 40 vs 33%; and RR, 10 vs 4% (P = 0.008). Additional coding sequence mutations were ruled out. The R558 allele was more common in patients than in controls (30 vs 21 %, P = 0.002), conferring an odds ratios for AF of 1.6 (95% confidence interval 1.2-2.2). The SCN5A R558 allele, present in one-third of the population, thus constitutes a risk factor for lone AF and may increase susceptibility to sodium channel blocker-induced proarrhythmia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据